Recent News

• 06.04.2026 - Gelteq Establishes Center of Excellence in China to Accelerate Product Development and Commercial Expansion
• 05.20.2026 - Gelteq Commences Veterinary Medicine Clinical Trial to Support an FDA Regulatory Pathway
• 05.12.2026 - Gelteq Announces USD $3.5 Million Strategic Debt Financing to Accelerate Commercialization and Support Revenue Growth
• 02.11.2026 - Gelteq and Healthy Extracts to Expand Gel-Based Nutrition Technologies with New Strategic Manufacturing & Commercial Partnership
• 01.13.2026 - Gelteq Announces Positive Preclinical Results Showing Increased Medicinal Cannabinoid Absorption Using Its Oral Gel Delivery Platform
• 12.16.2025 - Gelteq Furthers Asia Presence Through Partnership with Hong Kong Flag Football Program
• 12.09.2025 - Gelteq Signs Three Year Sales Agreement with Shenzhen Mana Health Management Co. Strengthening Gelteq’s Nutritional Product Expansion into China
• 12.05.2025 - Gelteq Preclinical Study Demonstrates Enhanced Oral Delivery of Oil-Soluble and Poorly Soluble Drugs Using Its Gel-Based Platform
• 12.02.2025 - Gelteq to Present at Investor Summit Virtual on December 9, 2025
• 11.24.2025 - Gelteq Announces Positive Preclinical Results Demonstrating Enhanced Bioavailability Using Its Proprietary Gel-Based Drug Delivery Platform

Recent Filings

• 06.02.2026 - 6-K Report of foreign issuer [Rules 13a-16 and 15d-16]
• 06.02.2026 - EX-99.1 EX-99.1
• 05.26.2026 - 6-K Report of foreign issuer [Rules 13a-16 and 15d-16]
• 03.24.2026 - 6-K Report of foreign issuer [Rules 13a-16 and 15d-16]
• 03.18.2026 - 3 Initial statement of beneficial ownership of securities
• 03.18.2026 - 3 Initial statement of beneficial ownership of securities
• 03.18.2026 - 3 Initial statement of beneficial ownership of securities
• 03.18.2026 - 3 Initial statement of beneficial ownership of securities
• 12.09.2025 - EX-99.1 EX-99.1
• 12.09.2025 - 6-K Report of foreign issuer [Rules 13a-16 and 15d-16]